Opus Genetics (IRD) Depreciation & Amortization (IS) (2010 - 2014)
Opus Genetics (IRD) reported Depreciation & Amortization (IS) of $3744.0 for Q3 2014, down 61.18% year-over-year from $9645.0 in Q3 2013, and down 61.12% on a QoQ basis from $9630.0 in Q2 2014.
Opus Genetics (IRD) has 5 years of Depreciation & Amortization (IS) data on file, last reported at $3744.0 in Q3 2014.
- Quarterly Depreciation & Amortization (IS) fell 61.18% year-over-year to $3744.0 in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $31355.0 (down 18.39% YoY) and the FY2013 annual result came in at $37133.0, down 12.39% from the prior year.
- Depreciation & Amortization (IS) eased to $3744.0 in Q3 2014 per IRD's latest filing, from $9630.0 in the prior quarter.
- Across five years, Depreciation & Amortization (IS) topped out at $15816.0 in Q4 2010 and bottomed at $3744.0 in Q3 2014.
- The 5-year median for Depreciation & Amortization (IS) is $10194.5 (2011), against an average of $10339.9.
- The widest annual swing landed in 2012, when Depreciation & Amortization (IS) grew 5.87%; it then tumbled 61.18% in 2014.
- Tracing IRD's Depreciation & Amortization (IS) over 5 years: stood at $15816.0 in 2010, then tumbled by 35.72% to $10166.0 in 2011, then advanced by 0.56% to $10223.0 in 2012, then fell by 12.58% to $8937.0 in 2013, then slumped by 58.11% to $3744.0 in 2014.
- Per Business Quant, the three latest IRD Depreciation & Amortization (IS) figures stand at $3744.0 (Q3 2014), $9630.0 (Q2 2014), and $9044.0 (Q1 2014).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 127,436.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 3,744.00 |
| Jun 30, 2014 | 9,630.00 |
| Mar 31, 2014 | 9,044.00 |
| Dec 31, 2013 | 8,937.00 |
| Sep 30, 2013 | 9,645.00 |
| Jun 30, 2013 | 9,235.00 |
| Mar 31, 2013 | 9,316.00 |
| Dec 31, 2012 | 10,223.00 |
| Sep 30, 2012 | 10,721.00 |
| Jun 30, 2012 | 10,721.00 |
| Mar 31, 2012 | 10,721.00 |
| Dec 31, 2011 | 10,166.00 |
| Sep 30, 2011 | 10,127.00 |
| Jun 30, 2011 | 10,650.00 |
| Mar 31, 2011 | 14,127.00 |
| Dec 31, 2010 | 15,816.00 |
| Sep 30, 2010 | 11,663.00 |
| Jun 30, 2010 | 11,633.00 |